Clinical Trial Update: Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and immunogenicity of two GMZ2 malaria vaccine doses (30 and 100 µg) in Gabonese children aged 1-5 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• GMZ2 malaria vaccine (GMZ2)

Snippet

Sponsor: African Malaria Network Trust | Conditions: Malaria | Phase 1 | Status: UNKNOWN